{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:12:31Z","timestamp":1765260751759,"version":"3.46.0"},"reference-count":47,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["PI22\/01804"],"award-info":[{"award-number":["PI22\/01804"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: Lung transplantation (LT) is a rescue therapy for end-stage pulmonary diseases, including systemic autoimmune diseases. The aim of this study was to analyse the evolution of patients with systemic sclerosis (SSc) who, after undergoing LT, become negative for antinuclear antibodies (ANA) and to assess whether they have different clinical and prognostic characteristics than patients who do not become negative. Material and Methods: A retrospective, descriptive analysis was performed over a cohort of patients with a diagnosis of SSc, who underwent unilateral or bilateral LT between 2006 and 2021 at the Vall d\u2019Hebron University Hospital. Clinical and analytical data were obtained from these patients by reviewing their electronic medical records. Two groups of patients were compared: those who tested negative for ANA after LT and those who did not. Statistical analysis was performed with SPSS Statistics 20.0. Results: Eighteen patients were included. The most frequent indication for LT was interstitial lung disease (ILD) combined with pulmonary hypertension (PH), in 13 (72%) patients. All had ANA before the LT (n = 18), and regarding specific SSc autoantibodies, anti-topoisomerase I was presented in 44% (n = 8), anti-U11\/U12RNP in 17% (n = 3), anti-RNA Polymerase III in 11.1% (n = 2), anti-Ro52 in 11% (n = 2) and anti-centromere in 6% of individuals (n = 1). 39% (n = 7) of the patients had negative post-LT ANA, 44% (n = 8) had declining titres, and 17% (n = 3) had stable ANA titres. Titres did not increase in any case after LT. Those patients who became ANA-negative after LT were those who had significantly lower titres before LT. No statistically significant differences between groups were found related to pre-LT clinical characteristics, immunosuppressive regimen applied after LT, or in post-LT outcomes. A non-significant trend towards better survival was observed in patients who became ANA negative, with a cumulative survival at 5 years of 85.7% compared to 72.7% among those who remained ANA-positive. Conclusions: Most patients with SSc clear ANA or reduce their levels after LT. A trend towards better survival was observed in this group, compared to the group of transplanted patients who remained positive.<\/jats:p>","DOI":"10.3390\/jcm14248673","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Change in Antinuclear Antibodies After Lung Transplantation in Patients with Systemic Sclerosis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-162X","authenticated-orcid":false,"given":"V\u00edctor","family":"Barreales-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Internal Medicine Service, University Health Care Complex of Le\u00f3n, 24008 Leon, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-507X","authenticated-orcid":false,"given":"Alfredo","family":"Guillen-Del-Castillo","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Berastegui","sequence":"additional","affiliation":[{"name":"Lung Transplant and Pulmonary Vascular Pathology Unit, Pneumology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Enfermedades Respiratorias, 28003 Madrid, Spain"},{"name":"ERN-LUNG (European Reference Network on Rare Respiratory Diseases), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2650-9238","authenticated-orcid":false,"given":"Manuel","family":"L\u00f3pez-Meseguer","sequence":"additional","affiliation":[{"name":"Lung Transplant and Pulmonary Vascular Pathology Unit, Pneumology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Enfermedades Respiratorias, 28003 Madrid, Spain"},{"name":"ERN-LUNG (European Reference Network on Rare Respiratory Diseases), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Monforte","sequence":"additional","affiliation":[{"name":"Lung Transplant and Pulmonary Vascular Pathology Unit, Pneumology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Enfermedades Respiratorias, 28003 Madrid, Spain"},{"name":"ERN-LUNG (European Reference Network on Rare Respiratory Diseases), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Saez-Gimenez","sequence":"additional","affiliation":[{"name":"Lung Transplant and Pulmonary Vascular Pathology Unit, Pneumology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Enfermedades Respiratorias, 28003 Madrid, Spain"},{"name":"ERN-LUNG (European Reference Network on Rare Respiratory Diseases), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8806-3908","authenticated-orcid":false,"given":"Ana","family":"Villar","sequence":"additional","affiliation":[{"name":"Lung Transplant and Pulmonary Vascular Pathology Unit, Pneumology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Enfermedades Respiratorias, 28003 Madrid, Spain"},{"name":"ERN-LUNG (European Reference Network on Rare Respiratory Diseases), 08035 Barcelona, Spain"},{"name":"Interstitial Lung Disease Unit, Department of Pulmonology, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1igo","family":"Ojanguren","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red, Enfermedades Respiratorias, 28003 Madrid, Spain"},{"name":"ERN-LUNG (European Reference Network on Rare Respiratory Diseases), 08035 Barcelona, Spain"},{"name":"Interstitial Lung Disease Unit, Department of Pulmonology, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Codina-Clavaguera","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8115-5330","authenticated-orcid":false,"given":"Alejandra","family":"Fern\u00e1ndez-Luque","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Sanz-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Immunology, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-1154","authenticated-orcid":false,"given":"Laura","family":"Vi\u00f1as-Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Immunology, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janire","family":"Perurena-Prieto","sequence":"additional","affiliation":[{"name":"Department of Immunology, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Triginer-Gil","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-1539","authenticated-orcid":false,"given":"Luis","family":"Alcal\u00e1-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Digestive System Research Unit, Department of Digestive Diseases, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Bravo","sequence":"additional","affiliation":[{"name":"Lung Transplant and Pulmonary Vascular Pathology Unit, Pneumology Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3390-9029","authenticated-orcid":false,"given":"Carmen Pilar","family":"Sime\u00f3n Aznar","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2397198320924873","article-title":"Overall Mortality","volume":"6","author":"Moore","year":"2021","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and Survival in Systemic Sclerosis: Systematic Review and Meta-Analysis","volume":"44","author":"Royo","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the Epidemiology, Risk Factors, and Disease Outcomes of Systemic Sclerosis","volume":"32","author":"Ingegnoli","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification Criteria for Systemic Sclerosis","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and Prevalence of Systemic Sclerosis","volume":"60","author":"Bairkdar","year":"2021","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpainsymman.2015.12.314","article-title":"The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study","volume":"52","author":"Racine","year":"2016","journal-title":"J. Pain Symptom Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and Predicting Mortality from Systemic Sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic Sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and Safety of Nintedanib in SSc-ILD Treated with Mycophenolate","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): Subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226429","article-title":"EULAR Recommendations for the Treatment of Systemic Sclerosis: 2023 Update","volume":"84","author":"Lescoat","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E757","DOI":"10.1097\/TXD.0000000000001209","article-title":"Lung Transplantation in Systemic Sclerosis: A Practice Survey of United States Lung Transplant Centers","volume":"7","author":"Sehgal","year":"2021","journal-title":"Transplant. Direct"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-017-0650-z","article-title":"Lung Transplantation in Patients with Systemic Sclerosis","volume":"19","author":"Shah","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5858\/2000-124-0071-GFCUOT","article-title":"Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens","volume":"124","author":"Kavanaugh","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2007.12.001","article-title":"The Many Faces of Scleroderma","volume":"34","author":"Steen","year":"2008","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102583","DOI":"10.1016\/j.autrev.2020.102583","article-title":"Autoantibodies to Stratify Systemic Sclerosis Patients into Clinically Actionable Subsets","volume":"19","author":"Mahler","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chepy, A., Bourel, L., Koether, V., Launay, D., Dubucquoi, S., and Sobanski, V. (2022). Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.930970"},{"key":"ref_18","first-page":"106","article-title":"Serodiscordant Patients with Systemic Sclerosis: When Antibody Does Not Correspond to Skin Involvement","volume":"38","author":"Espinosa","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.semarthrit.2014.11.006","article-title":"Antinuclear Antibody-Negative Systemic Sclerosis","volume":"44","author":"Salazar","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_20","first-page":"S127","article-title":"Prevalence and Clinical Profiles of \u201cAutoantibody-Negative\u201d Systemic Sclerosis Subjects","volume":"32","author":"Hudson","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/jdv.12512","article-title":"Disappearance of Autoantibodies to RNA Polymerase III after Treatment","volume":"29","author":"Tanahashi","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3899\/jrheum.150105","article-title":"Specific ANA Level Changes after B-Cell Depletion Therapy in Systemic Sclerosis","volume":"43","author":"Bonroy","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2015.1069888","article-title":"Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: A promising surveillance marker of therapy?","volume":"44","author":"Kielhauser","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/rheumatology\/keaa736","article-title":"Lung Transplantation Improved Autoimmunity and Scleroderma in Diffuse Cutaneous SSc: A Case Report","volume":"60","author":"Tanaka","year":"2021","journal-title":"Rheumatology"},{"key":"ref_25","first-page":"202","article-title":"Scleroderma: Classification, Subsets and Pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/kead236","article-title":"Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2","volume":"63","author":"Thomas","year":"2024","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud Phenomenon and Digital Ulcers in Systemic Sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00296-024-05699-x","article-title":"Heart involvement in patients with systemic sclerosis\u2014What have we learned about it in the last 5 years","volume":"44","author":"Nadel","year":"2024","journal-title":"Rheumatology International"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1093\/rheumatology\/keaf433","article-title":"Esophageal Dysmotility Patterns Are Associated with Distinct Clinical Phenotypes and Prognosis in Patients with Systemic Sclerosis","volume":"64","author":"Aguilar","year":"2025","journal-title":"Rheumatology"},{"key":"ref_31","first-page":"SI82","article-title":"Clinico\u2013Pathological Phenotypes of Systemic Sclerosis\u2013Associated Myopathy: Analysis of a Large Multicentre Cohort","volume":"62","author":"Kisluk","year":"2022","journal-title":"Rheumatology"},{"key":"ref_32","first-page":"485","article-title":"Diagnosis and Management of Primary Heart Involvement in Systemic Sclerosis","volume":"35","author":"Mavrogeni","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1093\/rheumatology\/keaf424","article-title":"Decreasing Prevalence and Cumulative Incidence of Scleroderma Renal Crisis Over Time: Associated Factors Identified from the RESCLE Registry","volume":"64","author":"Gordo","year":"2025","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"K\u0105dziela, M., Fija\u0142kowska, A., Kraska-Gacka, M., and Wo\u017aniacka, A. (2025). The Art of Interpreting Antinuclear Antibodies (ANAs) in Routine Diagnostic Practice. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155322"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/rheumatology\/keab279","article-title":"Anti-RNPC-3 Antibody Predicts Poor Prognosis in SSc-ILD","volume":"61","author":"Severino","year":"2021","journal-title":"Rheumatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/rheumatology\/kead520","article-title":"Anti-VCP-Like Autoantibody Associated with Calcinosis and Cancer Risk in SSc","volume":"63","author":"Colobran","year":"2024","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103328","DOI":"10.1016\/j.jaut.2024.103328","article-title":"Expanding the Landscape of Systemic Sclerosis-Related Autoantibodies through RNA Immunoprecipitation Coupled with Massive Parallel Sequencing","volume":"149","author":"Triginer","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1378\/chest.105.3.837","article-title":"Single Lung Transplantation in Patients with Systemic Disease","volume":"105","author":"Levine","year":"1994","journal-title":"Chest"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2017.03.012","article-title":"Lung Transplantation in Systemic Sclerosis: A Single-Center Cohort","volume":"85","author":"Berastegui","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/BOR.0000000000000904","article-title":"Scleroderma Autoantibodies in Guiding Monitoring and Treatment","volume":"34","author":"Shah","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Outcome-Based Classification in Systemic Sclerosis Using Autoantibodies and Skin Subsets","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2397198319870667","article-title":"Pathogenic Roles of Autoantibodies in Systemic Sclerosis","volume":"5","author":"Hoa","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Maria, A.T.J., Partouche, L., Goulabchand, R., Rivi\u00e8re, S., Rozier, P., Bourgier, C., Le Quellec, A., Morel, J., No\u00ebl, D., and Guilpain, P. (2019). Cancer and Systemic Sclerosis: Immune Relationships. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03112"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/kez341","article-title":"Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma","volume":"59","author":"Hinze","year":"2020","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological Autoantibody Internalisation in Myositis","volume":"83","author":"Pak","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.healun.2023.12.007","article-title":"Chronic lung allograft dysfunction is associated with an increased number of non-HLA antibodies","volume":"43","author":"Xu","year":"2024","journal-title":"J. Heart Lung Transplant."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:15:07Z","timestamp":1765257307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":47,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248673"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248673","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}